Literature DB >> 26684767

The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience.

Eric Bouffet1, Jeffrey C Allen2, James M Boyett3, Allen Yates4, Floyd Gilles5, Peter C Burger6, Richard L Davis7, Laurence E Becker8, Ian F Pollack9, Jonathan L Finlay10.   

Abstract

OBJECT The impact of central pathology review on outcome has been described in pediatric patients with high-grade glioma (HGG). The objective of this report was to analyze the impact of the central pathology review on outcome in the subgroup of patients with institutional diagnosis of HGG of the spinal cord enrolled in the Children's Cancer Group 945 cooperative study. METHODS Five neuropathologists centrally reviewed the pathology of the 18 patients with HGG of the spinal cord who were enrolled in the study. These reviews were independent, and reviewers were blinded to clinical history and outcomes. A consensus diagnosis was established for each patient, based on the outcome of the review. RESULTS Of 18 patients, only 10 were confirmed to have HGG on central review. At a median follow-up of 12 years, event-free and overall survival for all 18 patients was 43.2% ± 13.3% and 50% ± 13.4%, respectively. After central review, 10-year event-free and overall survival for confirmed HGGs and discordant diagnoses was 30% ± 12.5% versus 58.3% ± 18.8% (p = 0.108) and 30% ± 12.5% versus 75% ± 14.2% (p = 0.0757), respectively. CONCLUSIONS The level of discordant diagnoses in children and adolescents with institutional diagnosis of HGG of the spinal cord was 44% in this experience. However, there was no significant difference in outcome between patients with confirmed and discordant diagnosis. This group of tumor deserves a specific attention in future trials.

Entities:  

Keywords:  AA = anaplastic astrocytoma; CCG = Children's Cancer Group; EFS = event-free survival; GBM = glioblastoma multiforme; HGG = high-grade glioma; OS = overall survival; central review; malignant glioma; oncology; pathology; spinal cord; spine

Mesh:

Year:  2015        PMID: 26684767      PMCID: PMC5040185          DOI: 10.3171/2015.10.PEDS1581

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  21 in total

1.  Spinal cord astrocytomas: long-term results comparing treatments in children.

Authors:  G J Przybylski; A L Albright; A J Martinez
Journal:  Childs Nerv Syst       Date:  1997-07       Impact factor: 1.475

2.  Pediatric low-grade and ependymal spinal cord tumors.

Authors:  T E Merchant; E N Kiehna; S J Thompson; R Heideman; R A Sanford; L E Kun
Journal:  Pediatr Neurosurg       Date:  2000-01       Impact factor: 1.162

3.  Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.

Authors:  P Chastagner; C Kalifa; F Doz; E Bouffet; J C Gentet; M M Ruchoux; S Bracard; E Desandes; D Frappaz
Journal:  Pediatr Blood Cancer       Date:  2007-11       Impact factor: 3.167

4.  Pathologist interobserver variability of histologic features in childhood brain tumors: results from the CCG-945 study.

Authors:  Floyd H Gilles; C Jane Tavaré; Laurence E Becker; Peter C Burger; Allan J Yates; Ian F Pollack; Jonathan L Finlay
Journal:  Pediatr Dev Pathol       Date:  2007-09-25

5.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.

Authors:  R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

6.  Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.

Authors:  Maryam Fouladi; Daniel L Hunt; Ian F Pollack; Gregor Dueckers; Peter C Burger; Laurence E Becker; Allen J Yates; Floyd H Gilles; Richard L Davis; James M Boyett; Jonathan L Finlay
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

7.  Spinal cord malignant astrocytomas. Clinicopathologic features in 36 cases.

Authors:  Mariarita Santi; Hernando Mena; Kondi Wong; Kelly Koeller; Cara Olsen; Elisabeth J Rushing
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

8.  Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.

Authors:  J L Finlay; J M Boyett; A J Yates; J H Wisoff; J M Milstein; J R Geyer; S J Bertolone; P McGuire; J M Cherlow; M Tefft
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

9.  Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Authors:  Andrey Korshunov; Jochen Meyer; David Capper; Arne Christians; Marc Remke; Hendrik Witt; Stefan Pfister; Andreas von Deimling; Christian Hartmann
Journal:  Acta Neuropathol       Date:  2009-06-19       Impact factor: 17.088

10.  Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.

Authors:  Douglas J Hyder; Lillian Sung; Ian F Pollack; Floyd H Gilles; Allen J Yates; Richard L Davis; James M Boyett; Jonathan L Finlay
Journal:  J Neurooncol       Date:  2007-01-25       Impact factor: 4.506

View more
  1 in total

1.  Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study.

Authors:  Jiang Liu; Minghui Zheng; Wuyang Yang; Sheng-Fu L Lo; Judy Huang
Journal:  J Neurooncol       Date:  2018-05-23       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.